All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Chi-Fu Jeffrey Yang, MD
Disclosure(s): AstraZeneca: Advisory Board (Ongoing); Genentech: Advisory Board (Ongoing)

Ammara A. Watkins, MD, MPH

Presentations

1. Expanding Eligibility Criteria for Lung Cancer Screening: Pro
   Douglas E. Wood, MD, FACS, FRCSEd
    
2. Expanding Eligibility Criteria for Lung Cancer Screening: Con
   Chris Slatore, MD, MS
    
3. Discussion
    
4. After Screening Surgical Follow Up
   Cherie Erkmen, MD
   Disclosure(s): AstraZeneca; BMS; Merck; Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer, USA: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
    
5. Incidental Nodules vs. Screen-Detected Nodules: Is There a Difference?
   Neel Chudgar, MD
   Disclosure(s): AstraZeneca: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); LUNGevity: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
    
6. Lung Cancer and Lung Cancer Screening in Individuals Without a Smoking History
   Natalie Lui, MD
   Disclosure(s): Centese: Sponsored research agreement (Terminated, June 30, 2024); Intuitive Foundation: Research grant (Terminated, June 30, 2024); Intuitive Surgical: Consultant (Ongoing)
    
7. Discussion
    
8. Reassessing Efficacy: Understanding Failures in Lung Cancer Screening Despite Low-Dose CT Protocol Adherence
   Victoria Shiqi Wu
    
9. The Harms of Lung Cancer Screening: Telling Truths and Dispelling Myths
   Hari B. Keshava, MD MS FACS
   Disclosure(s): AstraZeneca (Any division): Consultant (Ongoing), Speaker (Ongoing)
    
10. Novel Adjuncts to Lung Cancer Screening to Expand Screening Eligibility and Reduce Screening Harms
    Jane Yanagawa, MD
    Disclosure(s): AstraZeneca: Advisory Board (Ongoing), Steering Committee Member (Ongoing); OncLive: Lung Cancer Workshop Attendee (Ongoing)
     
11. Discussion
     
12. Achieving Equitable Care for Underrepresented Minority Patients with a Lung Cancer Screening Program
    Azante Griffith